The accumulation of multiple CS-mutations also seems to be important for the development and progression of AML, as multiple CS-mutations, such as in STAG2, RUNX1, SRSF2, and ASXL1, preferentially co-occur in patients with high-risk MDS who later develop sAML. This evidence concerns the gene RUNX1 and acute myeloid leukemia.